Comparing the current results to its competitors, Solid Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 25.59 %, recorded in the same quarter.
Solid Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, focusing on treatments for neuromuscular diseases including Duchenne and Friedreich's ataxia (FA), cardiac diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT), and gene therapy. Its competitors include large and small biopharmaceutical companies, academic research institutions, government agencies, and both public and private research organizations. Competitors may obtain regulatory approval earlier or develop more advanced or effective therapies, which could impact the company's ability to develop, market, or commercialize its product candidates. The company also competes with existing therapies and potential future treatments.
April 1, 2024
FDA s green flagging of SGT-003 complements Solid Biosciences previous success, as the gene therapy candidate has already been granted Orphan Drug and Fast Track Designations within the U.S.. Rare Pediatric Disease Designation, coupled with the previous recognitions, attributes a high level of confidence and promises a swifter process of conduction of clinical trials, review, and potential commercialization, representing an unprecedented milestone in DMD treatment. DMD is a devastating genetic disorder characterized by progressive muscle degeneration. Limited treatments are available to these patients, making the work of companies like Solid Biosciences crucial. The FDA s Special Categories of Designation (...
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Passage Bio Inc's business model focuses on developing and commercializing innovative genetic therapies for rare, monogenic central nervous system disorders.
Sources:
Solid Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Solid Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
